

References

- **AASLD (American Association for the Study of Liver Diseases), (2000):** Update on viral hepatitis. Postgraduate Course. <https://www.aasld.org>.
- **Adinolfi LE, Gambardella M, Andreana A, et al. (2001):** Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. *Hepatology*; 33:1358–1364.
- **Adinolfi LE, Ingrosso D, Cesaro G, et al. (2005):** Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. *Hepatology*; 41:995-1003.
- **Afdhal NH, Dieterich DT, Pockros PJ, et al.(2004):** Epoetin alfa maintains ribavirin dose in HCVinfected patients: a prospective, double-blind, randomized controlledstudy. *Gastroenterology* 2004;126:1302-1311
- **Akuta N, Suzuki F, Sezaki H, et al.,(2006):** Predictive factors of virologic-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. *Journal of medical virology* 78:83-90
- **Alberti A. (2005):** Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanine aminotransferase levels. *J. Hepatol.* 2005; 42: 266-274.
- **Alfaleh FZ, Hadad Q, Khuroo MS, et al. (2004):** Peginterferon alpha-2b plus 40. ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi

patients commonly infected with genotype 4. Liver Int; 24(6):568-74.

- **Alter MJ (2006):** The epidemiology of viral hepatitis and HIV co infection. Journal of hepatology ;44:56-59
- **Antonelli A, Ferri C, Pampana A, et al., (2004) :** Thyroid disorders in chronic hepatitis C.Am J Med.; 117(1):10-3.
- **Armstrong GL , Walsey A , simard EP et al.,(2006):** The prevalance of hepatitis C virus infection in USA .Ann of Intern med; 144:705-714.
- **Arora S, O'Brien C, Zeuzem S. (2006):** Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha- 2a (40 kDa) plus ribavirin: impact on health-related quality of life. J Gastroenterol Hepatol; 21: 406-412.
- **Arrieta JJ, Rodriguez-Inigo E, Casqueiro M, et al.(2000):** Detection of hepatitis C virus replication by In situ hybridization in epithelial cells of anti-hepatitis C virus-positive patients with and without oral lichen planus. Hepatology 2000 Jul; 32(1): 97-103
- **Asselah T., Rubbia-Brandt L., Marcellin P., et al., (2006):** Steatosis in chronic hepatitis C: why does it really matter? Gut. 2006; 55(1):123-30.
- **Bacon BR and Shiffman ML. (2009):** Phase 2 randomized, double-blind, placebo- controlled study of nitazoxanide plus peginterferon and ribavirin in HCV genotype 1 patients: Interim analysis shows increase in EVR. J Hepatol; 50S: 381.

- **Bahtiyar G, Shin JJ, Aytaman A, et al., 2004:** Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights. *Current Diabetes Reports*; 4:194-198.
- **Batts KP, Ludwig J. (1995):** Chronic hepatitis. An update on terminology and reporting. *Am J Surg Pathol* 1995; 19: 1409-1417
- **Bedossa P, Dargere D, Paradis V.(2003):** Sampling variability of liver fibrosis in chronic hepatitis C. *Hepatology* 2003;38:1449-1457.
- **Bedossa P, Poynard T. (1996):** An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. *Hepatology* 1996; 24:289-293
- **Benhamou Y, Afdhal NH, Nelson DR. (2009):** A Phase III study of the safety and efficacy of viremide versus ribavirin in treatment-naïve Patients with chronic hepatitis C: ViSER1 Results *Hepatology*; 50:717-726.
- **Benhamou Y, Di Martino V, Bochet M. (2001):** Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. *Hepatology*; 34: 283-287.
- **Bennett CL, Silver SM, Djulbegovic B, et al. (2008):** Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. *Jama* 2008;299:914-924.
- **Berg T, Sarrazin C, Herrmann E. (2003):** Prediction of treatment outcome in patients with chronic hepatitis C: significance of

baseline parameters and viral dynamics during therapy. Hepatology; 37(3): 600-609.

- **Berg T, von Wagner M, Nasser S et al. (2006):** Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology; 130:1086–1097.
- **Berg T, von Wagner M, Nasser S, et al (2008):** Tailored Treatment for Hepatitis C. Clin Liver Dis 2008;12:507–528.
- **Bini EJ and Mehandru S. (2005):** Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels. Aliment Pharmacol Ther 2005; 23:777–785.
- **Bonacini M and Puoti M (2000):** Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. Arch Intern Med ;160(22):3365-73.
- **Booth J ,O’Gradg J and Neuberger J (2001):**Clinical guidelines of the management of hepatitis C .Gut. ;49 (Supl I):1-21
- **Brau N, Bini EJ, Currie S et al. (2006):** Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin. J Viral Hepat;13:242–249.
- **Bravo AA, Sheth SG, Chopra S. (2001) :** Liver biopsy. N Engl J Med; 344:495-500

- **Bressler BL, Guindi M, Tomlinson G et al. (2003):** High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. *Hepatology*; 38:639–644.
- **Bruchfeld A, Lindahl K, Reichard O. (2006):** Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. *J Viral Hepat*; 13:316-321.
- **Bruchfeld A, Lindahl K, Schvarcz R. (2002):** Dosage of ribavirin in patient with hepatitis C should be based on renal function: a population pharmacokinetic analysis. *Ther Drug Monit*; 24: 701–708.
- **Bruno R, Sacchi P, Ciappina V, et al.(2004):** Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized,controlled study. *Antiviral Ther* 2004; 9(4): 491-497.
- **Bruno R, Sacchi P, Maiocchi L, et al.(2005):** Area-under-the-curve for peginterferon alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naïve patients with chronic hepatitis C. *Antiviral Ther* 2005; 10(2): 201-205.
- **Buti M, Sanchez-Avila F, Lurie Y, et al.(2002):** Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. *Hepatology*;35:930-936.
- **Calleri G, Cariti G, Gaiottino F. (2007):** A short course of pegylated interferon-alpha in acute HCV hepatitis. *J Viral Hepat*; 14:116-121.

- ***Camma C, Bruno S, Di Marco V et al.,(2006):*** Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. *Hepatology* 2006 43(1):64-71.
- ***Carey WD, 2003:*** Tests and screening strategies for the diagnosis of hepatitis C. *Cleveland Clinic Journal*; 70:7-13.
- ***Carlsson T, Reichard O, Norkrans G, et al (2005):*** Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. *J Viral Hepatol* 2005; 12:473-480.
- ***Castera L, Vergniol J, Foucher J, LeBail B, et al.(2005):*** Prospective comparison of transient elastography, Fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. *Gastroenterology* 2005;128:343-350.
- ***Castera L., Foucher J., Bertet J., Couzigou P., et al. (2006):*** FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases. *Hepatology* 2006; 43: 373-374.
- ***Centers for Disease Control and prevention. (2008):*** Hepatitis B virus. Frequently asked question, division of viral hepatitis for health professionals. July 21, 2008.
- ***Charlton M , Pockros P, Harrison S (2006):*** Impact of obesity on treatment of chronic hepatitis C. *Hepatology* 2006, 43, 6,1177-1186.
- ***Cheruvattath R, Rosati MJ, Gautam M. (2007):*** Pegylated interferon and ribavirin failures: is retreatment an option? *Dig Dis Sci*; 52:732-736.

- ***Chevaliez S and Pawlotsky JM.(2007):*** Interferon-based therapy of hepatitis C. *Adv Drug Deliv Rev* 2007; 59:1222–1241.
- ***Chu CJ and Lee SD. (2008):***Hepatitis B virus/hepatitis C virus coinfection: Epidemiology, clinical features, viral interactions and treatment (review). *Journal of Gastroenterology and Hepatology*;23:512–520.
- ***Chung RT, Andersen J, Volberding P. (2004):*** Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. *N Engl J Med*; 351: 451-459.
- ***Colin C, Lanoir D, Touzet S, et al.(2001):*** Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. *J Viral Hepatol* 2001; 8:87-95.
- ***Colletta C., Smirne C., Fabris C., Toniutto P., et al. (2005):*** Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. *Hepatology* 2005; 42: 838-845.
- ***Conjeevaram HS, Fried MW, Jeffers LJ, et al.(2006):*** Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. *Gastroenterology* 2006; 131:470–477.
- ***Conjeevaram HS, Kleiner DE, Everhart JE, et al. (2007):*** Race, insulin resistance and hepatic steatosis in chronic hepatitis C. *Hepatology*; 45:80–87.

- **Corey KE, Ross AS, Wurcel A. (2006):** Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol; 4(10): 1278–1282.
- **Cornberg M, Hadem J, Herrmann E, et al. (2006):** Treatment with daily consensus interferon (CIFN) plus ribavirin in nonresponder patients with chronic hepatitis C: a randomized open label pilot study. J Hepatology; 44: 291-301.
- **Crawford DH, Roberts S, Weltman M, et al.(2008):** Baseline factors associated with rapid and early virological responses in HCV genotype 1 patients treated with induction dosing of pegylated interferon: the CHARIOT study. 43rd Annual Meeting of the European Association for the Study of the Liver 2008; 23-27.
- **Crockett SD and Keffe EB. (2005):** Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. Ann Clin Microbiol Antimicrob; 4:13-25
- **Crotty S, Cameron CE, Andino R.(2001):** RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci USA 2001; 98:6895–6900.
- **Dai CY, Huang JF, Hsieh MN, et al. (2009):** Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J.Heptol; 50(4): 712-718
- **Dalgard O, Bjoro K, Ring-LarsenH, et al. (2008):** Pegylated interferon alfa and ribavirin for 14 versus 24weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology; 47:35–42.

- **Darling J.M.; Fried M.W. (2009):** Nitazoxanide: beyond parasites toward a novel agent for hepatitis C. *Gastroenterology* 2009; 136(3):760-3.
- **Datta SD, Armstrong GL, Roome AJ et al., (2003):** Blood exposure and hepatitis C virus infections among emergency groups. *Arch intern med*; 163:2605-2610.
- **Davis GL, Wong JB, McHutchison JG, et al. (2003):** Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. *Hepatology*; 38:645–652.
- **Davis GL. (2006):** new therapies: oral inhibitors and immune modulators. *Clin Liver Dis*; 10:865-880.
- **De Franceschi L, Fattovich G, Turrini F, et al.(2000) :** Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. *Hepatology* 2000; 31:997–1004.
- **De Veer MJ, Holko M, Frevel M, et al.(2001):** Functional classification of interferon-stimulated genes identified using microarrays. *J. Leukocyte Biol* 2001; 69:912–920.
- **Desmet V.J.; Roskams T. (2004):** Cirrhosis reversal: a duel between dogma and myth. *J. Hepatol.* 2004; 40(5):860-7.
- **Desmet VJ, Gerber M, Hoofnagle JH, et al. (1994):** Classification of chronic hepatitis: diagnosis, grading and staging. *Hepatology*; 19:1513-1520.
- **Desmond CP, Roberts SK, Dudley F, et al. (2006):** Sustained virological response rates and durability of the response to

interferon-based therapies in hepatitis C patients treated in the clinical setting. *J Viral Hepat*; 13:311–315.

- ***Deuffic-Burban S, Poynard T, Sulkowski MS, et al. (2007):*** Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. *J Viral Hepat.*; 14: 107-115
- ***Dhalluin C, Ross A, Leuthold L-A, et al.(2005):*** Structural and biophysical characterization of the 40 kDa PEG interferon- α 2a and its individual positional isomers. *Bioconjugate Chem* 2005; 16 (3): 504-517.
- ***Di Bisceglie AM, Shiffman ML, Everson GT, et al. (2008):*** Prolonged therapy of advanced chronic hepatitis C with low-dose peg-interferon. *N Engl J Med.*; 359: 2429-2441.
- ***Di Bisceglie AM. (2006):*** Hepatitis C. *Clinical Hepatology* 2006; 2:235-248.
- ***Di Bisceglie AM. and Hoofnagle JH (2002):*** Optimal therapy of hepatitis C. *Hepatology* 2002; 36, S121–S127.
- ***Dienstag JL (2002):*** The role of liver biopsy in chronic hepatitis C. *Hepatology*; 36(Suppl): S152-S160.
- ***Distante S, Bjoro K, Hellum KB et al. (2002):*** Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. *Liver*; 22:269–275.
- ***Dixit NM, Layden-Almer JE, Layden TJ, et al.(2004):*** Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. *Nature* 2004; 432:922–924.

- **Doss W ,Esmat G ,El-sayed M et al., (2008):** Egyptian national control Strategy for viral hepatitis. National committee for control of viral hepatitis .Agency national de recherche sur le SIDA(ANRS) 6-12.
- **Dries V., Odenthal M., Schirmacher P. (2001):** Liver biopsy in chronic hepatitis C. Histopathology, molecular diagnostic analysis, and implications for therapeutic management. Pathology 2001; 22(6): 362-8.
- **El Makhzangy H, Esmat G, SaidM, et al (2009):** Response to Pegylated Interferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 4. Journal of Medical Virology 81:1576–1583.
- **El-Serag HB, Hampel H, Rabeneck L et al., (2002):** Extrahepatic manifestations of hepatitis C among United States male veterans.Hepatology.;36(6):1439-45.
- **El-Zayadi AR. (2009):** Hepatitis C comorbidities affecting the course and response to therapy: World J Gastroenterol; 28: 15(40): 4993-4999.
- **Erol S, Ozkurt Z. (2009):** Poor response to treatment with peg-INF containing regimens in Patient coinfectd with hepatitis B and hepatitis C virus: Hepatitis Monthly; 9(3): 224-228.
- **European Medicines Agency(2008):** Summary of product characteristics Pegasys ®[online]2008; Available from URL: <http://www.emea.eu.int>.
- **Everson GT, Hoefs JC, Seeff LB, et al. (2006):** Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology; 44:1675–1684.

- ***Farci P, Strazzera R, Alter HJ, et al. (2002):*** Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. *Proc Natl Acad Sci USA*; 99:3081–3086.
- ***Fargion S, Fracanzani AL, Sampietro M, et al. (1997):*** Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. *Eur J Gastroenterol Hepatol*; 9:497–503.
- ***Feld JJ, Nanda S, Huang Y, et al. (2007):*** Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. *Hepatology* 2007;46:1548–1563.
- ***Ferenci P, (2004):*** Predictors of response to therapy for chronic hepatitis C. *Semin Liver Dis. Vol.*,24:25-31
- ***Ferenci P, Fried MW, Shiffman ML, et al (2005):*** Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) / ribavirin. *J Hepatol* 2005; 43:453–471.
- ***Ferenci P, Laferl H, Scherzer TM, et al. (2008):*** Peginterferon Alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. *Gastroenterology* [Epub ahead of print].
- ***Ferrell L.D., Theise N.D., Scheuer P.J. (2002):*** Acute and chronic viral hepatitis. *Pathology of liver*, 4th edn. London: Churchill Livingstone; pp 313-362.
- ***Ferri C., Zignego A.L., Pileri S.A. (2002):*** Cryoglobulins. *J. Clin. Pathol.* 2002; 55:4-13.

- **Fireman, M.; Indest, D.W.; Blackwell, A.; et al. (2005):** Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care. Clin Infect Dis. 40(Suppl 5):S286-91.
- **Fissell RB, Bragg-Gresham JL, Woods JD. (2004):**Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int; 65(6):2335.
- **Fleig WE, Krummenerl P, Lesske J. (2004):** Diagnosis, progression and therapy of hepatitis C virus infection as well as viral infection in children and adolescents--results of an evidence based consensus conference of the German Society for Alimentary Metabolic Disorders and and in cooperation with the Hepatitis Competence Network. Gastroenterol; 42(8):703-4.
- **Forns X, Garcia-Retortillo M, Serrano T et al.(2003):** Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-396.
- **Foster GR, Fried MW, Hadziyannis SJ, et al.(2007):** Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40 kD) and ribavirin. J Gastroenterol 2007; 42(2):247-255.
- **Fracanzani AL, Conte D, Fraquelli M, et al. (2001):** Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology ; 33:647–651.

- **Frank C, Mohamed K, Strickland T, et al.(2000)**, The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. *Lancet* 2000;355: 887–891.
- **Fried MW, Hadziyannis SJ, Shiffman M, et al. (2008)**: Rapid viral response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis c virus infection. *J Hepatol*; 48 (Suppl.2):5A.
- **Fried MW, Shiffman M, Reddy KR, Smith C, et al.(2002)**: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; 347:975-982.
- **Gad RR, Males S, El Makhzangy H, et al. (2008)**: Predictors of a sustained virological response in patients with genotype 4 chronic hepatitisC. *Liver International* (2008) The Authors. Journal compilation Blackwell Munksgaard, 1112-1117.
- **Gaeta GB, Precone DF, Felaco FM, et al.(2002)** : Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in ‘real world’ patients with chronic hepatitis C. *Aliment Pharmacol Ther* 2002; 16:1633–1639
- **Gehrke SG, Stremmel W, Mathes I, et al. (2003)**: Hemochromatosis and transferrin receptor gene polymorphisms in chronic hepatitis C: impact on iron status, liver injury and HCV genotype. *J Mol Med*; 81:780–787.
- **Gerlach JT, Diepolder HM, Zachoval R. (2003)**: Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. *Gastroenterology*; 125(1):80-8.

- **Germer J.J., Vandenameele J. N., Mitchell P.S., Harmsen W.S., et al. (2004):** Automated sample preparation for the Trugene HIV-1 genotyping kit using the MagNA pure LC instrument. *Diagn. Microbiol Infect. Dis.* 2004; 49:59–61.
- **Ghany G. Marc, Doris B. Strader, David L. Thomas, et al.(2009):** Diagnosis, Management, and Treatment of Hepatitis C: An Update. *Hepatology*, April; 49: 1335-1374.
- **Giannini and Bréchet (2003) ,** Hepatitis C virus biology; *Cell Death and Differentiation* 2003;10:S27 ± S38
- **Giannini E, Botta F, Borro P, Risso P, et al.(2003):** Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in liver cirrhosis.*Gut* 2003; 52:1200-1205.
- **Glue P, Rouzier-Panis R, Raffanel C, et al (2000):** Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. *Clin. Pharmacol. Ther* 2000; 68, 556–567.
- **Hadziyannis SJ, Sette H, Morgan TR, et al (2004):** Peginterferon alfa- 2a (40 kilodaltons) and ribovirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. *Ann Intern Med* 2004; 140:346–355.
- **Hasan F, Asker H, Al Khaldi J, et al. (2004):** Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. *Am J Gastroenterol*; 99:1733–1737.
- **Heathcote Jand Main J. (2005):** Treatment of Hepatitis C; *J ViralHepat.* ; 12(3):223-235.

- **Hickman IJ, Clouston AD, MacDonald GA, et al. (2002):** Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. *Gut*; 51:89-94.
- **Hinrichsen H, Benahmou Y, Wedemeyer H. (2004):** HCV protease inhibitor-BILN 2061: can STAT-C drugs be designed that are equally effective across genotypes? *Gastroenterology*; 127:1347.
- **Hofer H, Osterreicher C, Jessner W, et al. (2004):** Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C. *J Hepatol*; 40:1018–1022.
- **Hoofnagle J (2002):** Course and outcomes of hepatitis C. *Hepatology*,2002;36:S21-S29.
- **Hui JM, Kench J, Farrell GC, et al.(2002):** Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. *J Gastroenterol Hepatol* 2002; 17:873–881.
- **Hwang SJ, Luo JC, Chu CW, et al. (2001):** Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. *J Gastroenterol Hepatol*; 16:190–195.
- **Ishak K, Baptista A, Bianchi L, et al. (1995):** Histologic grading and staging of chronic hepatitis. *J Hepatology*; 22: 696.699.
- **Jacobi C, Wenkel H, Jacobi A, Korn K, Cursiefen C, Kruse FE(2007):** Hepatitis C and ocular surface disease.*Am J Ophthalmol.*;144(5):705-711.
- **Jacobson IM, Brown Jr RS, Freilich B, et al (2007):** Peginterferon alfa-2b and weight-based or flat dose ribavirin in

- chronic hepatitis C patients: a randomized trial. *Hepatology* 2007; 46:971–981.
- **Jaeckel E, Cornberg M, Wedemeyer H. (2001):** Treatment of acute hepatitis C with interferon alfa-2b. *N Engl J Med*; 345:1452-1457.
 - **Jensen DM, Morgan TR, Marcellin P, et al. (2006):** Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ ribavirin therapy. *Hepatology*; 43:954–960.
 - **Jonas MM. (2002):** Children with hepatitis C. *Hepatology*; 36:S173-S178.
 - **Jorquera F, Monte MJ, Guerra J, et al. (2005):** Usefulness of combined measurement of serum bile acids and ferritin as additional prognostic markers to predict failure to reach sustained response to antiviral treatment in chronic hepatitis C. *J Gastroenterol Hepatol*; 20:547–554.
 - **Kamal SM, El Kamary SS, Shardell MD, et al. (2007):** Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. *Hepatology*; 46: 1732-1740.
 - **Kamal SM. (2009):** Hepatitis C genotype 4 therapy: increasing options and improving outcomes. *Liver Int*; 29 Suppl 1:39-48.
 - **Karino Y, Toyota J, Sugawara M, et al. (2003):** Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C. *J Gastroenterol Hepatol*; 18:404-410

- **Karnsakul W, Alford MK, Schwarz KB. (2009):** Managing pediatric hepatitis C: current and emerging treatment options, *Therapeutics and Clinical Risk Management*; 5: 651–660.
- **Kau A, Vermehren J and Sarrazin C (2008):** Treatment predictors of a sustained virologic response in hepatitis B and C. *Journal of Hepatology*;49 :634–651.
- **Keam SJ. and Cvetkovi´c RS.(2008):** Peginterferon- α -2a (40 kD) Plus Ribavirin, A Review of its Use in the Management of Chronic Hepatitis C Mono-Infection. *Drugs* 2008; 68(9):1273-1317.
- **Keefe, E.B. (2003):** Liver transplantation. Current status and novel approaches to liver replacement *Gastroenterology*; 120: 749.
- **Kessel A., Rosner I., Zuckerman E. (2000):** Use of antikeratin antibodies to distinguish between rheumatoid arthritis and polyarthritis associated with hepatitis C infection. *J. Rheumatol* 2000; 27:610-2.
- **Khanna VJ, Shieh S, Benjamin J, et al.(2000):** Necrolytic acral erythema associated with hepatitis C: effective treatment with interferon alfa and zinc. *Arch Dermatol* 2000 Jun; 136(6): 755-7
- **Khuroo MS, Khuroo MS and Dahab ST. (2004):** Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. *Aliment Pharmacol Ther*; 20:931–938.
- **Kidney disease: improving global outcomes (KDIGO). (2008):** *Kidney Int Suppl*: S1-S99.
- **Kim WR (2002):** The burden of hepatitis C in the United States. *Hepatology*; 36: S30-S34.

- **Kleiner DE.(2005):** The liver biopsy in chronic hepatitis C: A view from the other side of the microscope. *Semin Liver Dis.* 2005;25:52-64
- **Knodell RG, Ishak KG, Black WC, et al.(1981):**Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. *Hepatology* 1981;1:431-435
- **Kobayashi S, Takeda T, Enomoto M, et al (2007):** Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. *Liver Int* 2007; 27:186-191.
- **Koda M., Matunaga Y., Kawakami M., Kishimoto Y., et al. (2007):** FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. *Hepatology* 2007; 45: 297-306.
- **Kronenberger B, Welsch C, Forestier N. (2008):** Novel hepatitis C drugs in current trials. *Clin Liver Dis*; 12:529–550.
- **Kumar D, Farrell GC, Fung C, et al (2002):** Hepatitis C virus genotype 3 is cytopathic to hepatocytes. Genotype-specific reversal of hepatic steatosis after sustained response to antiviral therapy. *Hepatology*; 36:1266- 1272.
- **Lau JY, Tam RC, Liang TJ., et al.(2002):** Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. *Hepatology* 2002; 35:1002–1009.

- **Lauer G And Walker B (2001):** Hepatitis C Virus Infection. N Engl J Med,2001;345, (1), 41-52.
- **Lavanchy D and McMahon B(2000):** Worldwide prevalence and prevention of hepatitis C. In: Hepatitis C, Liang TJ, Hoofnagle JH, eds. San Diego, Academic Press.185-202.
- **Lechner F. et al.(2001):** Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med; 191:1499–1512.
- **Lecube A, Hernandez C, Simo R, et al. (2007):** Glucose abnormalities are an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Am J Gastroenterol;102:2189–2195.
- **Lee S and Abdo A.,(2003):** Predicting antiviral treatment response in chronic hepatitis C: how accurate and how soon?. Journal of Antimicrobial Chemotherapy 2003; 51,487–491.
- **Lee WM, Dienstag JL, Lindsay KL, et al. (2004):** Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon non-responders. Control Clin Trials; 25: 472-492.
- **Levey AS, Coresh J, Balk E. (2003):** National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med; 139:137-147.
- **Lindahl K, Schvarcz R, Bruchfeld A, et al.(2004):** Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepatol 2004; 11:84–87.

- **Lindahl K, Stahle L, Bruchfeld A, et al.(2005):** High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. *HEPATOLOGY* 2005;41:275-279.
- **Lindsay K, Manns MP, Gordon SC et al. (2008):** Clearance of HCV at 5 year follow-up for peginterferon alfa-2b with or without ribavirin is predicted by sustained virologic response at 24 weeks post-treatment. *Gastroenterology*; 134 (Suppl. 1):772A.
- **Lindsay KL, Treppe C, Heintges T, et al.(2001):** A randomized, doubleblind trial comparing PEGylated interferon alfa-2b to interferon α -2b as initial treatment for chronic hepatitis C. *Hepatology* 2001; 34:395–403.
- **Liu C., Zhu H., Subramanian G.M., Moore P.A., et al. (2007):** Anti-hepatitis C virus activity of albinterferon alfa-2b in cell culture. *Hepatol. Res.* 2007; 37(11):941-7.
- **Lonardo A. , Loria P, Adinolfi L, et al.,(2006):** Hepatitis C and steatosis: a reappraisal. *Journal of Viral Hepatitis* 2006, 13, 73–80.
- **Lyra AC, Fan X and Di Bisceglie AM (2004):** Molecular biology and clinical implication of hepatitis C virus. *Brazilian Journal of Medical and Biological Research*; 37: 691-695.
- **Maheshwari A and Thuluvath PJ. (2010):** Management of Acute Hepatitis C. *ClinLiverDis*; 14:169–176.
- **Males S, Gad RR, Esmat G et al. (2007):** Serum alpha-fetoprotein level predicts treatment outcome in chronic hepatitis C. *Antivir Ther*; 12(5):797-803

- **Mangia A, Minerva N, Bacca D, et al. (2008):** Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. *Hepatology*; 47:43–50.
- **Mangia A, Santoro R, Minerva N, et al. (2005):** Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. *N Engl J Med*; 352:2609–2617.
- **Manns MP, McHutchison JG, Gordon SC, Rustgi VK, et al.(2001):** Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2a for initial treatment of chronic hepatitis C: a randomized trial. *Lancet* 2001;358:958-965.
- **Marcellin P, Lurie Y, Rodrigues Torres M. (2007):**The safety and efficacy of taribavirin plus pegylated interferon alfa 2a versus ribavirin plus pegylated interferon alfa 2a in therapy naïve patients infected with HCV: *Hepatology*; 46 (Suppl 1): S7.
- **Martin LM, Younossi ZM, Price L, et al.(2001):** The impact of ribavirin induced anemia on health-related quality of life. *Hepatology* 2001; 34(suppl):600A. Abstract.
- **McGuire BM, Julian BA, Bynon JS Jr, Cook WJ, King SJ, Curtis JJ, Accortt NA, Eckhoff DE.(2006):** Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. *Ann Intern Med*.;144(10):735-41.
- **McHutchison J(2004).** Understanding Hepatitis C: *Am J Manag Care*.2004;10:S21-S29.
- **McHutchison JG, Dusheiko G, Shiffman ML, et al.(2007) :** Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. *N Engl J Med* 2007;357:2227-2236.

- **McHutchison JG, Poynard T, Pianko S, et al. (2000):** The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. *Gastroenterology*; 119:1317–1323.
- **McKee D.H., Young A.C., Alonso-Dominguez A., Tembl J.I., et al. (2000):** Neurologic complications associated with hepatitis C virus infection. *Neurology* 2000; 55: 459 - 459.
- **Mignogna MD, Lo Muzio L, Lo Russo L, et al.(2000):** Oral lichen planus: different clinical features in HCV-positive and HCV-negative patients. *Int J Dermatol* 2000 Feb; 39(2): 134-9.
- **Missiha S, Heathcote J, Arenovich T et al. (2007):** Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. *Am J Gastroenterol*; 102:2181-2188
- **Mondelli M.(2003),** Natural history of hepatitis C virus infection. *Journal of Biological Regulators and Homeostatic Agents* 2003;17: 128-32.
- **Moucari R, Ripault MP, Martinot-Peignoux M et al.(2009):** Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4.Gut.; 58(12):1662-9.
- **Muir AJ, Bornstein JD and Killenberg PG. (2004):** Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. *N Engl J Med*; 350:2265–2271.

- **Murray KF, Rodrigue JR, Gonzalez-Peralta RP. (2007):** Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection. Clin Trials; 4:661-673.
- **Myers R.P., Ratziu V., Imbert-Bismut F., Poynard T., et al. (2002):** Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am. J. Gastroenterol. 97(9):2419-25.
- **Nafeh MA, Medhat A, Shehata M, et al (2000):** Hepatitis C in community in upper Egypt: I. Cross- sectional survey. Am J Trop Med Hgy 2000; 63:236-241.
- **National Institutes of Health (NIH). (2002):** Consensus development program and the state-of-the-science conferences. Management of hepatitis C. Washington, DC: National Institutes of Health;1-46.
- **Novozhenov V, Zakharova N, Vinogradova E. (2007):** Phase II study of omega interferon alone or in combination with ribavirin in subjects with chronic hepatitis C genotype-1 infection. J Hepatol; 46(3):631-9.
- **Okafor O and Segun O, 2004:** A comparative analysis of six current histological classification schemes and scoring systems used in chronic hepatitis reporting. Rev Esp Patol; 37:269-277.
- **Orland JR, Wright TL, Cooper S. (2001):** Acute hepatitis C. Hepatology; 33: 321-327.
- **Ortiz V, Berenguer M, Rayon JM et al. (2002):** Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol; 97:2408–2414.

- **Palumbo E. (2009):** Treatment for Chronic Hepatitis C in Children: A Review American Journal of Therapeutics; 16: (5) 446-450.
- **Pascu M, Martus P, Hohne M, et al. (2004):** Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut; 53:1345–1351.
- **Patel K, Norris S, Lebeck L et al (2006):** HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C. Hepatology 2006; 43(2):241–249.
- **Patton, H.M.; Patel, K.; Behling, C.; et al. (2004):** The impact of steatosis on disease progression and early virological response in chronic hepatitis C patients. J. Hepatology 40 (3) 533 -535.
- **Pawlotsky JM (2002):** Molecular diagnosis of viral hepatitis. Gastroenterology; 122: 1554-1568.
- **Pawlotsky JM, Ben Yahia , et al., (2004):** Immunologic disorders in C virus chronic active hepatitis :A prospective case control study . Hepatology ;19:841
- **Pearlman BL, Ehleben C and Saifee S. (2007):** Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology; 46:1688–1694.
- **Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, et al.(2002):** Rapid suppression of hematopoiesis by standard or pegylated interferon- alpha. Gastroenterology 2002; 123:141–151.
- **Penin F., Dubuisson J., Rey F.A., Moradpour D., et al. (2004):** Structural biology of hepatitis C virus. Hepatology. 2004; 39:5-19.

- **Perelson AS et al.(2005):** New kinetic models for the hepatitis C virus. *Hepatology* 2005; 42: 749–754.
- **Perry CM and Jarvis B.(2001):** Peginterferon- α -2a (40 kD), a review of its use in the management of chronic hepatitis C. *Drugs* 2001;61(15): 2263-2288.
- **Pockros PJ, Shiffman ML, Schiff ER, et al.(2004) :** Epoetin alfa improves quality of life in anemic HCVinfected patients receiving combination therapy. *HEPATOLOGY* 2004;40: 1450-1458.
- **Pothoff A, Wedemeyer H, Boecher WO. (2008):** The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. *J Hepatol*; 49: 688-694.
- **Powell EE, Jonsson JR and Clouston AD, (2005):** Steatosis: co-factor in other liver diseases. *Hepatology*; 42:5-13.
- **Poynard T, McHutchison J, Goodman Z et al. (2000):** Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. *Hepatology*; 31:211–218.
- **Poynard T, Ratziu V, Charlotte F et al. (2001):** Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. *J Hepatol*; 34:730–739
- **Poynard T, Ratziu V, McHutchison J, et al. (2003):** Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. *Hepatology*; 38: 75-85.

- **Poynard T., Halfon P., Castera L., Munteanu M., et al. (2007):** Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin. Chem. 2007; 53(9):1615-22.
- **Poynard T., Munteanu M., Ngo Y., Torres M., et al. (2006):** Diagnostic value of FibroTest with normal serum aminotransferases. Hepatology 2006; 43: 374-375.
- **Putoi M, Airoidi M, Bruno et al ., (2002):** Hepatitis B co – infection in human immuno -deficiency virus-infected subjects . AIDS Rev; 4:27-35.
- **Raimondo G, Brunetto MR, Pontisso P. (2006):** Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-co-infected patients. Hepatology; 43: 100–7.
- **Raison CL, Demetrashvili M, Capuron L, et al.(2005):** Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005;19:105-123.
- **Ramos-Casals M, Mañá J, Nardi N, et al. (2005):** Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine (Baltimore). ;84(2):69-80
- **Ray SC, Arthur RR, Carella A, et al. (2000):** Genetic epidemiology of hepatitis 4. C virus throughout Egypt. J Infect Dis; 182(3):698-707.
- **Reddy KR, David RN, Zeuzem S, et al.(2009):** Ribavirin: Current role in the optimal clinical management of chronic hepatitis C. J Hepatol 2009; 50:402–411.

- **Reesink HW, Zeuzem S, Weegink CJ. (2006):** Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. *Gastroenterology*; 131:997-1002.
- **Regev A, Berho M, Jeffers LJ. (2002):** Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. *Am J Gastroenterol*; 97:2614-2618.
- **Reiss Gand Keffe EB. (2005):** Role of liver biopsy in the management of chronic liver disease: selective rather than routine. *Rev Gastroenterol Disord*; (5):195-205.
- **Rigopoulou EI, Abbott WG, Williams R, et al. (2007):** Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus. *Antiviral Res* 2007; 5:36–42.
- **Roberts EA and Yeung L (2002):** Maternal –infant Transmission of hepatitis C virus infection. *Hepatology*; 36:106-113.
- **Rocha CM, Perez RM, Ferreira AP. (2006):** Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. *Liver Int*; 26:305-310.
- **Rockey DC and Bissell DM (2006):** Noninvasive measures of liver fibrosis. *Hepatology*; 43 (Suppl): S113-S120.
- **Rodriguez -Torres M, Sulkowski M, Chung RT, et al. (2007):** Association of pre-treatment and on-treatment factors with rapid virological response in HCV genotype 1 infected patients treated with PEGIFN α -2a/RBV [abstract no. 1305]. *Hepatology* 2007; 46 (4 Suppl 1):817A.

- **Romero-Gomez M, Del Mar Vilorio M, Andrade RJ, et al. (2005):** Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. *Gastroenterology*; 128: 636-641.
- **Ross AS, Bhan AK, Pascual M, et al., 2004:** Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. *Clin Transplant*; 18:166-173.
- **Rossignol J.F., Elfert A., El-Gohary Y., Keeffe E.B., et al. (2009):** Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. *Gastroenterology* 2009; 136(3):856-62.
- **Roulot D, Bourcier V, Grando V, et al (2007):** Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. *J Viral Hepat* 2007; 14: 460–7.
- **Sabry AA, Sobh MA, Sheaaashaa HA, et al.(2002)** Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy. *Nephrol Dial Transplant.* ;17(11):1924-30.
- **Sagir A, Erhardt A, Schmitt M, et al. (2008):** Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. *Hepatology*; 47: 592-595.
- **Sakr MA, Esmat G, Hamid WA, et al.(2006):** Effect of body mass index, diabetes mellitus and hepatic steatosis on response to peg-interferon therapy in chronic HCV patients genotype 4. *Ain shams faculty of medicine* 2006; 144- 153.

- **Salama MM, Abou Gabal AK, Tharwa ES, et al.(2010):** Gamma glutamyl traspeptidase and alphafetoprotein: Are they predictors of treatment response in chronic hepatitis C patients? National liver institute, Menoufiya university 2010; 79-85.
- **Salama MM, Gameel KA, El Shereafy MS et al. (2007):** Assessment of steatosis in chronic hepatis C patients responders & nonresponders to combined pegylated interferon and ribavarin therapy. National liver institute, Menoufiya university 2007; 6: 80-90; 3: 40-43
- **Salmeron J, Casado J, Rueda PM, et al. (2008):** Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin. J Clin Virol; 41:264–269.
- **Sanchez-Tapias JM, Diago M, Escartin P, et al. (2006):** Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology; 131:451–460.
- **Sandrin L, Fourquet B, Hasquenoph JM, Yon S, et al.(2003):** Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29:1705-1713.
- **Sarrazin C, Gartner BC, Sizmann D, et al. (2006):** Comparison of conventional PCR with realtime PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. J Clin Microbiol; 44:729–737.

- **Schering Corporation (2006):** PEG-Intron (Peginterferon alfa-2b) powder for injection: US prescribing information [online] 2006; Available from URL: www.pegintron.com.
- **Scheuer PJ.(1991):** Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13:372-374
- **Schiff E, Michael F and Willis C (2007):** HepatitisC. Schiff'S disease of the liver .Gary D.Tenth Edition ,part 2.30;819-834.
- **Scott JD and Gretch DR.(2007);** Molecular diagnostics of hepatitis C virus infection: a systematic review. Jama 2007; 297:724-732.
- **Searle J, Leggett BA, Crawford DHG, et al.(2002):** . Iron storage diseases. In: MacSween RN, Burt AD, Portmann BC et al, eds. Pathology of the Liver, 4th ed. London, England: Churchill Livingstone; 2002:257-272
- **Sebastiani G.; Alberti A. (2006):** Noninvasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J. Gastroenterol. 2006; 12: 3682-3694.
- **Seeff LB, Miller RN, Rabkin CS. (2000):** 45Years follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000; 132:105-11.
- **Seeff LB., (2005):** Natural history of hepatitis C. Hepatology. Rev. Vol.,2:88-96
- **Seigel CA, Silas AM, Suriawinata AA, Van Leeuwun DJ. (2005):** Liver biopsy: when and how? Cleveland Clin J Med 2005; 72:199-224.

- **Sharma RK, Bansal SB, Gupta A. (2006):**Chronic hepatitis C virus infection in renal transplant: treatment and outcome. Clin Transplant; 20:677-683.
- **Shepard C.W., Finelli L., Alter M.J. (2005):** Global epidemiology of hepatitis c virus infection. Lancet Infect. Dis. 2005; 5:558-567.
- **Sherman KE, Rouster SD, Chung RT. (2002):** Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis; 34: 831-837.
- **Sherman M, Yoshida E M, Deschenes M. (2006):** Peginterferon alfa α 2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut; 55(11): 1631–1638.
- **Shiffman ML, SuterF, Bacon BR et al (2007):** Peg interferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357:124–134.
- **Shintani Y, Fujie H, Miyoshi H, et al. (2004):** Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology; 126:840–848.
- **Silva IS, Ferraz ML, Perez RM, et al. (2004):** Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol; 19:314–318.
- **Simmonds P, Bukh J, Combet C, Deléage G, et al.(2005):** Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42:962-973.

- ***Singer ME and Younossi ZM (2001):*** Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. *Am J Med* 3: 614-621.
- ***Soza A, Everhart JE, Ghany MG. (2002):***Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. *Hepatology*; 36:1273-1279.
- ***Sporea I, Danila M, Sirli R, et al.(2006):*** Comparative Study Concerning the Efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in Patients with Chronic Viral C Hepatitis. *Gastrointestin Liver Dis* 2006;15(2):125-130.
- ***Steckelberg J (2007):*** Hepatitis C: How common is sexual transmission?.Mayo Clinic Staff, Nov. 17.[www. Mayo Clinic.com /health/AN0070](http://www.MayoClinic.com/health/AN0070).
- ***Strader D.B., Wright T., Thomas D.L., Seeff L.B. (2004):*** Diagnosis, management, and treatment of hepatitis C. American Association for the Study of Liver Diseases Practice Guidline. *Hepatology* 2004; 39:1147-1171.
- ***Sulkowski M, Shiffman ML, Afdhal NH et al.(2008):*** Treatment-related anemia but not epoetin use (EPO) is associated with higher SVR rates among persons treated with peginterferon (PEG)/ribavirin (RBV): Results from the IDEAL Study. 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2008). San Francisco; Abstract 1851.

- **Tanaka ,Y.; Agha ,S.; Saudy , N .; et al (2004) :** Exponential spread of hepatitis C virus genotype 4 a in Egypt. Journal of molecular science .
- **Tassopoulos NC. (1999):** Treatment of patients with chronic hepatitis C and normal ALT levels. J Hepatol; 31(1):193-6.
- **Teuber G, Pascu M, Berg T et al.(2003):** Andomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. J Hepatol 2003; 39: 606-613.
- **Thomopoulos KC, Theocharis GJ, Tsamantas AC, et al., (2005):** Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol; 17:149-153.
- **Thuluvath PJ, Krok KL, Segev DL. (2007):** Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States. Liver Transpl; 13:719-724.
- **Torriani FJ, Rodriguez-Torres M, Rockstroh JK. (2004):**Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med; 351:438-450.
- **Vo NV, Young KC, Lai MM.(2003):** Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase. Biochemistery 2003; 42:10462–10471.
- **Von Wagner M, Huber M, Berg T. (2005):** Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology; 129(2):522-7.

- **Waked IA, Rewisha EA, Abd ELwahed AS, et al. (2009):** Early, end of treatment and sustained virological response of interferon plus ribavirin, does it differ in patients with chronic hepatitis c with normal versus elevated trasaminases? National liver institute, Menoufiya university 2009; 87-93
- **Wakil A and Merezban Z (2006):** Hepatitis C in Egypt. In Egypt today magazine. .HCV adovacte ,2006.WWW. HCV adovacte.org.
- **Washington K., Wright K., Shyr Y., Hunter E.B., et al. (2000):** Hepatic Stellate Cell Activation in Nonalcoholic Steatohepatitis and Fatty Liver. Hum. Pathol. Jul; 31(7):822-8.
- **Watt K, Veldt B, Charlton M. (2009):** A Practical guide to the management of HCV infection following liver transplantation. American Journal of Transplantation; 9: 1707–1713.
- **Weisner, R.H.; Sorrell, M.; and Willani, F. (2003):** Report of the first International Liver Transplantation Society Expert Panel Consensus Conference of Liver Transplantation.
- **Wiegand J, Deterding K, Cornberg M. (2008):** Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon, J Antimicrob. Chemother; 62: 860 - 865.
- **Williams R (2006):** Global challenges in liver disease.Hepatology; 44: 521-526.
- **World Health Organization (2008):** Hepatitis B : Key facts. WHO media center. August 2008 No 204:1-4.
<http://www.who.int/mediacentre/factsheets/fs204/en/> Accessed on August 2008.

- **Yao x, Dao-Zhen X, Zhi-Meng L, et al. (2005):** predictive factors for sustained response to interferon treatment in patients with chronic hepatitis C: a randomized, open and multi-center controlled trial. *Hepatobiliary pancreat Dis Int*, 2005; 4 :213-219.
- **Yu ML, Dai CY, Lee LP. (2006):** A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels. *Liver Int*; 26:1187-1195.
- **Zekri AR, Bahnassy AA, Ramadan AS et al.(2001):** . Hepatitis C virus genotyping versus serotyping in Egyptian patients. *Infection* 2001; 29: 24-26.
- **Zeuzem S (2008):** Interferon-based therapy for chronic hepatitis C: current and future perspectives. *nature clinical practice J Gastroenterol Hepatol* 2008; 5(11):610-622.
- **Zeuzem S, Buti M, Ferenci P. (2006):** Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. *J Hepatol*; 44(1): 97-103.
- **Zeuzem S, Diago M, Gane E et al.(2003):** Ontrolled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with peginterferon alfa-2a (40 kD) (Pegasys) and ribavirin (Copegus). *AASLD 2003* (abstract).
- **Zeuzem S, Diago M, Gane E. (2004):** peinterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. *Gastroenterology*; 127 (6): 1724 - 32.

- ***Zeuzem S, Feinman SV, Rasenack J. (2000):*** Peginterferon alfa-2a in patients with chronic hepatitis C. *N Engl J Med*; 343(23):1666-72.
- ***Zhu B, Zhang P, Wang XH et al. (2006):*** A virological response study of serum leptin level and insulin resistance on the antiviral effect in patients with chronic hepatitis C ; 14(12):887-9.
- ***Ziol M, Handra-luca A, Kettaneh A, Christidis C, et al.(2005):*** Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. *Hepatology*; 2005;41:48-54.
- ***Zobair M.; Younossi M.D. (2008):*** New Directions in Hepatitis C Therapy. A Look at the Evolving Therapeutic Arsenal; From Mescape Gastroenterology, Hepatitis C Expert Column. Published: 09/05/2008.
- ***Zuckerman E., Yeshurun D., Rosner I. (2001):*** Management of hepatitis C virus-related arthritis. *Bio. Drugs* 2001; 15:573-84.